Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 29,075 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Sitagliptin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas

Conditions: Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery
Interventions: Fospropofol disodium, Placebo + Midazolam, Fentanyl; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy, Obese
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypophosphatasia
Interventions: asfotase alfa; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
U.S. locations: 2
States / cities: Lakewood, Colorado • Pittsburgh, Pennsylvania

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Advanced Solid Tumor
Interventions: SGN1; Drug
Lead sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more

Conditions: Head and Neck Cancer
Interventions: capecitabine, Surgery, chemotherapy and/or radiotherapy; Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy Volunteers
Interventions: LY4178256, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Los Alamitos, California • Salt Lake City, Utah

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Vallhala, New York

Conditions: Healthy
Interventions: Dabigatran etexilate mesylate, Odalasvir (ODV), Simeprevir (SMV); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Nausea and Vomiting, Postoperative
Interventions: Amisulpride Injection, Dexamethasone; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Sheffield, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Healthy
Interventions: LY4005130, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatic Impairment
Interventions: DS-3201b; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
Interventions: PTHrP (1-36); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 24 Years to 35 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions: HIPEC, Carboplatin, Paclitaxel; Procedure · Drug
Lead sponsor: Andrea Jewell; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Gonorrhoea
Interventions: Meningococcal Group B Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions: Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Robbinsdale, Minnesota

Conditions: Neoplasms
Interventions: RG1507; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Aurora, Colorado • New Brunswick, New Jersey • Houston, Texas

Conditions: Healthy
Interventions: ibuzatrelvir, carbamazepine ER; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: inhaled mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more

Conditions: Ulcerative Colitis (UC), Crohn's Disease
Interventions: Risankizumab, Cytochrome P450 (CYP) Substrates; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Coronado, California • DeLand, Florida • Margate, Florida + 1 more

Search by objective public record fields.

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Study of SGN1 in Patients With Advanced Solid Tumor

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

A Study of LY4178256 in Healthy Participants

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

A Study of LY4005130 in Healthy Participants

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease